Machelle Sanders - 08 Feb 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Director
Signature
/s/ Jessica Dickerson, by power of attorney
Issuer symbol
BCRX
Transactions as of
08 Feb 2022
Net transactions value
$0
Form type
4
Filing time
10 Feb 2022, 16:06:28 UTC
Previous filing
25 Jan 2022
Next filing
09 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Non-Qualified Stock Option Award $0 +26,667 $0.000000 26,667 08 Feb 2022 Common Stock 26,667 $17.20 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan.
F2 The option vests 1/36 per month for a period of 36 months, beginning on March 8, 2022.